YU47185B - Postupak za aktiviranje heterolognih eukariotskih proteina, pripremljenih gen-tehnologijom koji imaju disulfidne mostove polse ekspresije u prokariotima - Google Patents

Postupak za aktiviranje heterolognih eukariotskih proteina, pripremljenih gen-tehnologijom koji imaju disulfidne mostove polse ekspresije u prokariotima

Info

Publication number
YU47185B
YU47185B YU179686A YU179686A YU47185B YU 47185 B YU47185 B YU 47185B YU 179686 A YU179686 A YU 179686A YU 179686 A YU179686 A YU 179686A YU 47185 B YU47185 B YU 47185B
Authority
YU
Yugoslavia
Prior art keywords
expression
pref
prokariots
polse
eukariotic
Prior art date
Application number
YU179686A
Other languages
English (en)
Other versions
YU179686A (en
Inventor
S. Fischer
R. Mattes
Original Assignee
Boehringer Mannheim Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh. filed Critical Boehringer Mannheim Gmbh.
Priority to SI8611796A priority Critical patent/SI8611796B/sl
Publication of YU179686A publication Critical patent/YU179686A/xx
Priority to HRP-1796/86A priority patent/HRP921075B1/xx
Publication of YU47185B publication Critical patent/YU47185B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

POSTUPAK ZA AKTIVIRANJE HETEROLOGNIH EUKARIOTSKIH PROTEINA, PRIPREMLJENIH GEN-TEHNOLOGIJOM KOJI IMAJU DISULFIDNE MOSTOVE POLSE EKSPRESIJE U PROKARIOTIMA, putem razaranja celije, solubiliziranja pod uslovima denaturisanja i redukovanja i aktiviranja pod oksidacionim uslovima, u prisustvu GSH/GSSG, naznace n time, sto se u stupnju aktiviranja radi pri pH-vrednosti 9 do 12, i pH-vrednosti 9,5 do 11, koncentraciji GSH 0,1 do 20 mmol/l, koncentraciji GSSG 0,01 do 3 mmol/l, kao i koncentraciji GSH 0,2 do 10 mmol/l, i/ili koncentraciji GSSG 0,05 do 1 mmol/l, i sa kon-centracijom sredstva za denaturisanje koja ne izaziva denaturisanje, a u odsustvu o-jodozobenzoata, sto se eventualno posle solubiliziranja, a pre aktiviranja izvodi stupanj preciscavaja, sto se aktiviranje izvodi eventualno bez prethodnog izdvajanja sredstva za denaturisanje/ redukovanje, pri cemu se reakcioni rastvor posle denaturisanja/redukovanja razblazuje sa puferom za aktiviranje, a pri sledecem aktiviranju koncentracija GSSG prevazilazi zaostalu koncentraciju DTE, sto se izvodi ekspresija, npr. u E. coli ili P. putida, sto se u stupnju aktiviranja kao sredstvo za denaturisanje upotrebljava npr. arginin, gvanidin-hidrohlorid i/ili bar jedno jedinjenje opste formule R2-CO-NRR1 (I), u kojoj R i R1 oznacavaju H ili alkil, sa 1 do 4 atoma ugljenika, a R2 oznacava H ili NHR1, ili alkil, sa 1 do 3 atoma ugljenika, sto koncentracija arginina i/ili gvanidin-hidrohlorida iznosi npr. 0,1 do 1,0 mol/l, u prvom redu 0,25 do 0,8 mol/l, sto koncentracija jedinjenja opste formule I iznosi, npr. 0,5 do 4 mol/l, u prvom redu 1 do 3,5 mol/l, sto se u stupnju aktiviranja eventualno radi u prisustvu proteina koji nema proteolitsko dejstvo, u prvom redu u prisustvu govedjeg serumskog albumina, sto se razaranje celije vrsi npr. pomocu ultra-zvuka, dispergovanja pod visokim pritiskom ili lizozimom, kao i u razblazenom vodenom puferskom rastvoru, u prvom redu u 0,1 mol/l Tris, pri neutralnoj do slabo kiseloj pH-vrednosti, sto se posle razaranja celije eventualno uklanjaju nerastvorni sastojci, sto se u stupnju solubiliziranja prvenstveno radi pri alkalnoj pH-vrednosti, u prisustvu redukcionog sredstva iz merkapto-grupe, kao DTE, beta-merkaptoetanola ili GSH, a u prisustvu sredstva za denaturisanje, kao gvanidin-hidroh-lorida i/ili jedinjenje opste formule I, sto se eventualno vrsi preciscavanje i izdvajanje sredstava za redukovanje, oksidovanje ili denaturisanje, pomocu hromatografije sternog razdvajanja, ili dijal-ize i sto se eventualno posle stupnja aktiviranja izvodi stupanj preciscavanja, pomocu dijalize. Prijava sadrzi jos 1 nezavisan i 3 zavisna zahteva.
YU179686A 1985-10-23 1986-10-21 Postupak za aktiviranje heterolognih eukariotskih proteina, pripremljenih gen-tehnologijom koji imaju disulfidne mostove polse ekspresije u prokariotima YU47185B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8611796A SI8611796B (sl) 1985-10-23 1986-10-21 Postopek za aktiviranje gentehnološko pripravljenih, heterolognih, eukariontskih proteinov, ki imajo disulfidne mostove, po ekspresiji v prokariontih
HRP-1796/86A HRP921075B1 (en) 1985-10-23 1992-10-16 Process for activating heterologous, eucariotic proteins, genetically engineered and presenting disulphide bridges after their expression in procaryotic cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853537708 DE3537708A1 (de) 1985-10-23 1985-10-23 Verfahren zur aktivierung von t-pa nach expression in prokaryonten

Publications (2)

Publication Number Publication Date
YU179686A YU179686A (en) 1988-06-30
YU47185B true YU47185B (sh) 1995-01-31

Family

ID=6284269

Family Applications (1)

Application Number Title Priority Date Filing Date
YU179686A YU47185B (sh) 1985-10-23 1986-10-21 Postupak za aktiviranje heterolognih eukariotskih proteina, pripremljenih gen-tehnologijom koji imaju disulfidne mostove polse ekspresije u prokariotima

Country Status (26)

Country Link
EP (3) EP0219874B1 (sh)
JP (2) JPH0728745B2 (sh)
KR (1) KR900009139B1 (sh)
AT (2) ATE98648T1 (sh)
AU (2) AU590029B2 (sh)
CA (1) CA1329157C (sh)
CZ (1) CZ280727B6 (sh)
DD (1) DD260517A5 (sh)
DE (3) DE3537708A1 (sh)
DK (2) DK175091B1 (sh)
ES (2) ES2061434T3 (sh)
FI (2) FI94050C (sh)
GR (2) GR920300062T1 (sh)
HK (2) HK153596A (sh)
HR (1) HRP921075B1 (sh)
HU (2) HUT43643A (sh)
IE (1) IE62634B1 (sh)
IL (1) IL80325A (sh)
PT (1) PT83609B (sh)
SI (1) SI8611796B (sh)
SK (1) SK278317B6 (sh)
SU (1) SU1607689A3 (sh)
UA (1) UA6023A1 (sh)
WO (1) WO1987002673A2 (sh)
YU (1) YU47185B (sh)
ZA (1) ZA868012B (sh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
JP2581668B2 (ja) * 1985-11-27 1997-02-12 三井東圧化学株式会社 ヒト正常細胞由来のヒト組織プラスミノ−ゲン活性化因子をコ−ドする新しいｄｎａ配列とそれを含むベクタ−及び細胞
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
AU621051B2 (en) * 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
DE3722082A1 (de) * 1987-07-03 1989-01-12 Behringwerke Ag Verfahren zur bestimmung der aktivitaet von serinproteasen oder serinproteaseinhibitoren
CA1340586C (en) * 1988-09-23 1999-06-08 Cetus Corporation Process for recovering microbially produced interferon-beta
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
EP0545999B1 (en) * 1990-08-20 1997-06-04 Novo Nordisk A/S Process for the preparation of biologically active IGF-1 using IGF-1 having an amino-terminal extension
ES2119779T3 (es) * 1990-09-05 1998-10-16 Southern Cross Biotech Pty Ltd Solubilizacion de proteinas en formas activas.
DE4037196A1 (de) * 1990-11-22 1992-05-27 Boehringer Mannheim Gmbh Verfahren zur reaktivierung von denaturiertem protein
DE4113750A1 (de) 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
AU3812993A (en) * 1992-03-24 1993-10-21 Synergen, Inc. Refolding and purification of insulin-like growth factor I
DK0600372T3 (da) 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
FR2729972B1 (fr) * 1995-01-31 1997-04-18 Sanofi Sa Procede d'extraction de proteines periplasmiques de microorganismes procaryotes en presence d'arginine
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
EP0904355B1 (de) * 1996-06-11 2004-03-03 Boehringer Mannheim Gmbh Verfahren zur aktivierung von denaturiertem protein
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
DE19850429A1 (de) * 1998-10-27 2000-05-04 Andre Schrattenholz Fragmente
EP1048732A1 (de) * 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen
EP1077263A1 (de) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
DE10105911A1 (de) 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Expression der rekombinanten Proteinase K aus Tritirachium album in Hefe
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
TWI476207B (zh) 2006-07-14 2015-03-11 Genentech Inc 重組蛋白之再摺疊
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
WO2011113601A1 (en) 2010-03-17 2011-09-22 Biogenerix Ag Method for obtaining biologically active recombinant human g-csf
US20130273607A1 (en) * 2010-10-20 2013-10-17 Medimmune, Llc Methods for processing inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
CN103852527B (zh) * 2012-12-05 2015-05-13 中国科学院大连化学物理研究所 一种高通量蛋白质样品预处理装置
US10457716B2 (en) 2014-08-06 2019-10-29 University Of Notre Dame Du Lac Protein folding and methods of using same
WO2018121703A1 (en) 2016-12-30 2018-07-05 Biogend Therapeutics Co., Ltd. Recombinant polypeptides, compositions, and methods thereof
EP4263568A1 (en) 2020-12-18 2023-10-25 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5135481A (ja) * 1974-09-18 1976-03-25 Fujiwa Kako Kk Kojundohitorokinaaze no seiho
US4468633A (en) 1982-04-28 1984-08-28 The Bendix Corporation Adjustable microwave power combiner for a plurality of coaxially mounted impatt diodes
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
GR79124B (sh) * 1982-12-22 1984-10-02 Genentech Inc
GB2138004B (en) * 1983-03-25 1987-05-13 Celltech Ltd A process for the production of a protein
JPS6051119A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The ウロキナ−ゼ乾燥製剤
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
FR2596360B1 (fr) * 1986-04-01 1989-02-17 Sotralentz Sa Conteneur sur palette avec dispositif de protection en treillis plie et renforce
JPH0651119A (ja) * 1992-07-28 1994-02-25 Sekisui Chem Co Ltd 位相差板の製造方法

Also Published As

Publication number Publication date
ATE131489T1 (de) 1995-12-15
DE3689404D1 (de) 1994-01-27
ZA868012B (en) 1987-06-24
WO1987002673A2 (en) 1987-05-07
DD260517A5 (de) 1988-09-28
HK153596A (en) 1996-08-16
GR920300062T1 (en) 1992-08-31
UA6023A1 (uk) 1994-12-29
FI872753A (fi) 1987-06-22
DK175091B1 (da) 2004-05-24
HK153496A (en) 1996-08-16
FI94050B (fi) 1995-03-31
CZ280727B6 (cs) 1996-04-17
IL80325A0 (en) 1987-01-30
HUT43643A (en) 1987-11-30
CZ752686A3 (en) 1996-01-17
IL80325A (en) 1992-06-21
JPH0824594B2 (ja) 1996-03-13
HRP921075B1 (en) 1999-02-28
DK200001897A (da) 2000-12-18
EP0393725B1 (de) 1995-12-13
PT83609B (pt) 1988-10-14
AU590029B2 (en) 1989-10-26
JPS62502895A (ja) 1987-11-19
YU179686A (en) 1988-06-30
IE62634B1 (en) 1995-02-22
FI95578B (fi) 1995-11-15
FI95578C (fi) 1996-02-26
JPH0728745B2 (ja) 1995-04-05
DE3537708A1 (de) 1987-04-23
WO1987002673A3 (fr) 1987-10-22
AU6599386A (en) 1987-05-19
DK320387D0 (da) 1987-06-23
ES2020498T3 (es) 1996-04-01
DE3650449D1 (de) 1996-01-25
FI933868A (fi) 1993-09-03
PT83609A (de) 1986-11-01
HRP921075A2 (en) 1995-06-30
AU4132189A (en) 1990-01-04
JPH04218387A (ja) 1992-08-07
DE3537708C2 (sh) 1993-07-08
EP0253823A1 (de) 1988-01-27
KR870700601A (ko) 1987-12-30
ES2020498A4 (es) 1991-08-16
EP0393725A1 (de) 1990-10-24
HU204855B (en) 1992-02-28
SI8611796B (sl) 1998-06-30
EP0219874A3 (en) 1988-02-10
FI933868A0 (fi) 1993-09-03
DK175109B1 (da) 2004-06-07
EP0219874A2 (de) 1987-04-29
AU607083B2 (en) 1991-02-21
IE862683L (en) 1987-04-23
FI94050C (fi) 1995-07-10
GR3018410T3 (en) 1996-03-31
EP0219874B1 (de) 1993-12-15
CA1329157C (en) 1994-05-03
SI8611796A (sl) 1996-10-31
KR900009139B1 (ko) 1990-12-22
SU1607689A3 (ru) 1990-11-15
SK278317B6 (en) 1996-10-02
FI872753A0 (fi) 1987-06-22
SK752686A3 (en) 1996-10-01
ATE98648T1 (de) 1994-01-15
DK320387A (da) 1987-06-23
ES2061434T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
YU47185B (sh) Postupak za aktiviranje heterolognih eukariotskih proteina, pripremljenih gen-tehnologijom koji imaju disulfidne mostove polse ekspresije u prokariotima
IE831024L (en) Human tissue plasminogen activator
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
DK394786A (da) Fremgangsmaade til rensning og aktivering af proteiner fra uoploeselige inklusionslegemer
DE58906984D1 (de) Aktivierung von gentechnologisch hergestellten, in Prokaryonten exprimierten Antikörpern.
Takahashi et al. Thrombospondin fragmentation by α-thrombin and resistance to γ-thrombin
CHIEN Threshold Limit Value of Subtilising
KR870700072A (ko) 사람의 내래성 암 억제인자의 제조방법